SV

Street Verdict

Analyst Scorecard

ADVIKLA.BO · BSE

ADVIK LABORATORIES LTD.

₹2.18

+4.81% (+₹0.1)

Prev. close

₹2.08

Volume

100

As of

16 Nov 2026

Price history

₹2.18-₹0.41 (-15.83%) · 3M
21 Jul 2025 → 16 Nov 2026
1.82.02.22.421 Jul20 Oct02 Mar13 Jul16 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range — no analyst has covered this yet.

Explore by date range →

Analyst opinions

No analyst calls on ADVIK LABORATORIES LTD. yet.

Fundamentals

About ADVIK LABORATORIES LTD.

MPS Pharmaa Limited manufactures, markets, trades in, and exports pharmaceutical products in India and internationally. The company offers generic products, including antibacterials, antiallergics, antifungals, anthelminthics, antihypertensives, antimalarials, antituberculosis, corticosteroids, erectile dysfunction, gastrointestinal agents, sedatives, and others, as well as analgesic, antipyretic, and anti-inflammatory products. It also provides ethical products, such as Wibatol, Wibatol-O, Robial, Twosum, Majispa, Arfa Gel, Stibomin, and Chewfe-C. In addition, the company exports its products to East Asia, Southeast Asia, the Middle East, South America, and Africa. The company was formerly known as Advik Laboratories Limited and changed its name to MPS Pharmaa Limited in December 2022. MPS Pharmaa Limited was incorporated in 1994 and is based in New Delhi, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Peeyush Kumar Aggarwal

Headquarters

New Delhi

Employees

18

Key stats

Market cap

₹3.98 Cr

Dividend yield

0.00%

EPS (TTM)

₹-0.55

Beta (1Y · daily vs NIFTY 50)

-0.00

Beta (5Y · monthly vs NIFTY 50)

0.12

Shares float

61.75 L

EPS · quarter ended Jun 2026

₹-0.12

Financial Performance

01 · Financials

-5 Cr-2.5 Cr0 Cr2.5 Cr₹-6000%-4000%-2000%0%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-3-2-10₹FY21FY22FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-200%0%200%400%FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

Left off as not meaningful (growth from a very small base, beyond ±400%): Sales FY21 (+1200%).

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr5 Cr10 Cr15 Cr₹0×50×100×150×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr5 Cr10 Cr15 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-5 Cr0 Cr5 Cr10 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss — as filed

Annual

Line itemFY23FY24FY25FY26
₹2.33 L₹9.37 L₹4.77 L₹3.56 L
Cost of materials consumed/expired
₹4.50 L———
Employee benefits expense
₹48.74 L₹52.77 L₹52.47 L₹53.31 L
Finance costs
₹5,368₹12,521₹4,983₹7,810
Depreciation and amortization expense
₹14.58 L₹14.67 L₹14.68 L₹14.68 L
Other expenses
₹41.55 L₹27.13 L₹23.96 L₹41.28 L
Total expenses (IV)
₹1.09 Cr₹94.70 L₹91.16 L₹1.09 Cr
Profit/(loss) before exceptional items and tax (III-IV)
₹-1.07 Cr₹-85.33 L₹-86.39 L₹-1.06 Cr
Profit/(loss) before tax (V-VI)
₹-1.07 Cr₹-85.33 L₹-86.39 L₹-1.06 Cr
(2) Deferred tax expenses/(Income)
₹-2.06 L₹-2.23 L₹2,783₹-3.79 L
(3) Earlier year MAT Credit Adjustment
——₹3.38 L—
Profit (Loss) after Tax
₹-1.05 Cr₹-83.10 L₹-89.79 L₹-1.02 Cr
₹-1.04 Cr———
—₹85,969†₹98,396₹78,269
Total Comprehensive Income for the period
₹1.52 L₹-82.24 L₹-88.81 L₹-1.01 Cr
(1) Basic
-0.55-0.43-0.47-0.53
(2) Diluted
-0.55-0.43-0.47-0.53

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.

‡ The company printed this figure on a line with no label (a bare subtotal under a block). Where the lines above add up to it, it is named after them; otherwise it is shown as “Unlabelled line”. The figure is the company’s own.

All years: standalone statements.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹10.19 Cr₹9.94 Cr₹9.33 Cr₹8.48 Cr
——₹6.76 Cr₹7.27 Cr₹7.46 Cr₹7.52 Cr
Stockholders' equity
——₹2.79 Cr₹1.97 Cr₹1.08 Cr₹6.85 L

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement — as filed

Annual

Line itemFY23
₹-86.55 L
₹-9.73 L

The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.

All years: standalone statements.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
ADVIK LABORATORIES LTD.₹3.98 Cr₹2.08—58.01-1488.5%109.80—+9.5%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

No stock news captured yet.